Patents Assigned to The Government of the United States of America as represented by the Secretary of the Department of Health & Human Services
-
Patent number: 10584355Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).Type: GrantFiled: October 31, 2016Date of Patent: March 10, 2020Assignees: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, GLAXOSMITHKLINE BIOLOGICALS SAInventors: Nancy J. Sullivan, Gary J Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
-
Patent number: 10568956Abstract: Described herein are dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes associated with immune enhancement. The disclosed dengue virus E-glycoproteins optionally further include mutations that introduce a strong CD4 T cell epitope. The disclosed E-glycoprotein polypeptides, or nucleic acid molecules encoding the polypeptides, can be used, for example, in monovalent or tetravalent vaccines against dengue virus.Type: GrantFiled: August 21, 2018Date of Patent: February 25, 2020Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Gwong-Jen J. Chang, Wayne D. Crill, Holly R. Hughes, Brent S. Davis
-
Patent number: 10557118Abstract: Compositions and methods are provided for preventing or treating neoplastic disease in a mammalian subject. A composition is provided which comprises an enriched immune cell population reactive to a human endogenous retrovirus type E antigen on a tumor cell. A method of treating a neoplastic disease in a mammalian subject is provided which comprises administering to a mammalian subject a composition comprising an enriched immune cell population reactive to a human endogenous retrovirus type E antigen, in an amount effective to reduce or eliminate the neoplastic disease or to prevent its occurrence or recurrence.Type: GrantFiled: January 7, 2019Date of Patent: February 11, 2020Assignee: The Government of the United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Richard William Wyatt Childs, Yoshiyuki Takahashi, Sachiko Kajigaya, Nanae Harashima
-
Patent number: 10507187Abstract: A graft containing a scaffold that includes a matrix in which are positioned mesenchymal progenitor cells (MPCs) has the capacity to substantially improve wound healing, including wounds resulting from injury to nerve, bone and vascular tissue. MPCs can be harvested from debrided muscle tissue following orthopaedic trauma. The traumatized muscle-derived progenitor cells are a readily available autologous cell source that can be utilized to effect or improve wound healing in a variety of therapeutic settings and vehicles.Type: GrantFiled: February 12, 2014Date of Patent: December 17, 2019Assignees: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC., THE UNITED STATES GOVERNMENT, AS REPRESENTED BY THE SECRETARY OF THE ARMY, U.S.A., THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Wesley M. Jackson, Leon J. Nesti, Rocky S. Tuan
-
Patent number: 10494435Abstract: Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (Kd) of 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human CD22 in a sample. In some cases, CD22 is soluble CD22. Methods of diagnosing a B-cell malignancy, or confirming a B-cell malignancy diagnosis, are disclosed herein that utilize these antibodies. Methods of treating a subject with a B-cell malignancy are also disclosed.Type: GrantFiled: February 3, 2017Date of Patent: December 3, 2019Assignee: The Government of the United States America as represented by the Secretary of the Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Xiaodong Xiao, Ira H. Pastan
-
Patent number: 10485879Abstract: A fusion molecule is provided that includes one or more inhibitory nucleic acids, a targeting polypeptide, and a nucleic acid binding moiety. The targeting polypeptide and the nucleic acid binding moiety include specific the amino acid sequences. A fusion molecule is also provided that includes one or more inhibitory nucleic acids, a targeting polypeptide, and a nucleic acid binding moiety adapted to bind a double-stranded RNA or to a small hairpin RNA. The targeting polypeptide being CCL27 or CCL11 or a fragment thereof.Type: GrantFiled: June 18, 2018Date of Patent: November 26, 2019Assignees: Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of HealthInventors: Bira Arya, Michael R. Simon
-
Patent number: 10449231Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.Type: GrantFiled: April 20, 2017Date of Patent: October 22, 2019Assignees: TAKEDA VACCINES, INC., The Government of the United States of America as Represented by the Secretary of the Department of Health and Human ServicesInventors: Dan T. Stinchcomb, Claire Kinney, Richard M. Kinney, Jill A. Livengood
-
Patent number: 10400031Abstract: Described herein is a method of identifying a monoclonal antibody (or antigen-binding fragment thereof) that specifically binds a plurality of lyssaviruses for use in post-exposure rabies prophylaxis or in the treatment of clinical rabies. The method includes using a naïve antibody phage display library to screen for phage clones that bind whole recombinant rabies virus or cells expressing glycoprotein from multiple lyssaviruses (such as RABV, MOKV and WCBV) and/or specifically bind recombinant glycoprotein from different lyssaviruses.Type: GrantFiled: October 5, 2017Date of Patent: September 3, 2019Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Todd G. Smith, Xianfu Wu
-
Patent number: 9864026Abstract: An implantable parametric circuit enables local signal amplification and wireless transmission of RF signals in connection with magnetic resonance imaging systems. The parametric circuit detects RF signal detected during magnetic resonance imaging procedure, amplifies the detected RF signal, and transmits the amplified RF signal in a wireless manner to an external pick-up coil. The parametric amplifier is also configured to use another RF signal generated by an external source as the primary power source. As a result, implanted or catheter coils could be used as a wireless signal transducer without the need for a battery or a power connection.Type: GrantFiled: March 29, 2012Date of Patent: January 9, 2018Assignee: The Government of The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Chunqi Qian, Joe Murphy-Boesch, Alan Koretsky, Stephen John Dodd
-
Patent number: 9803251Abstract: Disclosed herein are methods of detecting influenza virus in a sample from a subject. In some embodiments, the disclosed methods include contacting a sample with at least one primer 10-40 nucleotides in length wherein the at least one primer is capable of hybridizing to an influenza virus polymerase basic protein 1 (PB1) nucleic acid at least 70% identical to the nucleic acid sequence set forth as any one of SEQ ID NOs: 1-3, amplifying the PB1 nucleic acid or a portion thereof to produce an amplified PB1 nucleic acid, and detecting the amplified PB1 nucleic acid, wherein presence of the amplified PB1 nucleic acid indicates presence of influenza virus in the sample from the subject. In some examples, the primers comprise or consist of the nucleic acid sequence set forth as one of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 9, or SEQ ID NO: 10.Type: GrantFiled: March 7, 2013Date of Patent: October 31, 2017Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human ServicesInventor: Suxiang Tong
-
Patent number: 9687542Abstract: Disclosed herein is a robust system for the reverse genetics generation of a Rift Valley fever (RVF) virus replicon particle (VRPRVF) vaccine candidate. VRPRVF can actively synthesize viral RNA and proteins, but lack structural glycoprotein genes, preventing spread within immunized individuals and reducing the risk of vaccine-induced pathogenicity. Is it disclosed herein that VRPRVF immunization is both safe and efficacious, resulting in a robust immune response that is protective against RVF virus challenge within 24 hours of immunization. Provided herein are VRPRVF, methods of producing VRPRVF, and method of using VRPRVF for immunization against RVF virus infection.Type: GrantFiled: June 18, 2013Date of Patent: June 27, 2017Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Kimberly A. Dodd, Brian H. Bird, Cesar G. Albarino, Stuart T. Nichol
-
Patent number: 9487832Abstract: A process for detecting Neisseria meningitidis nucleic acid in a sample is provided including producing an amplification product by amplifying Neisseria meningitidis nucleotide sequence of the sodC gene or mRNA using a forward primer of SEQ ID NO: 1, and a reverse primer of SEQ ID NO: 2, and detecting the amplification product to detect Neisseria meningitidis in the sample. Also provided are reagents and methods for detecting and distinguishing Neisseria meningitidis from other infectious agents. A kit is provided for detecting and quantifying Neisseria meningitidis in a sample.Type: GrantFiled: October 11, 2011Date of Patent: November 8, 2016Assignee: The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventor: Jennifer Thomas
-
Patent number: 9453239Abstract: The invention provides modified vaccinia Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.Type: GrantFiled: August 29, 2005Date of Patent: September 27, 2016Assignees: Emory University, The Government of the United States of America, as represented by the Secretary Department of Health and Human Services, National Institutes of HealthInventors: Bernard Moss, Linda Wyatt, Harriet L. Robinson
-
Patent number: 9115400Abstract: Disclosed herein are point mutations in the LMNA gene that cause HGPS. These mutations activate a cryptic splice site within the LMNA gene, which leads to deletion of part of exon 11 and generation of a mutant Lamin A protein product that is 50 amino acids shorter than the normal protein. In addition to the novel Lamin A variant protein and nucleic acids encoding this variant, methods of using these molecules in detecting biological conditions associated with a LMNA mutation in a subject (e.g., HGPS, arteriosclerosis, and other age-related diseases), methods of treating such conditions, methods of selecting treatments, methods of screening for compounds that influence Lamin A activity, and methods of influencing the expression of LMNA or LMNA variants are also described.Type: GrantFiled: September 12, 2013Date of Patent: August 25, 2015Assignees: The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services, Research Foundation for Mental Hygiene, Inc., The Progeria Research Foundation, Inc.Inventors: B. Maria H. Eriksson, Francis S. Collins, Leslie B. Gordon, William Ted Brown
-
Patent number: 9079936Abstract: Derivatives of a novel antiproliferative factor comprising a glycopeptide is disclosed. In specific embodiments, the novel antiproliferative factor is associated with the bladder. Compositions, diagnostic kits and reagents, and methods of using the compounds for identifying and/or treating interstitial cystitis and cancer are disclosed. In particular embodiments, the glycopeptide comprises D-proline.Type: GrantFiled: August 18, 2009Date of Patent: July 14, 2015Assignees: University of Maryland, Baltimore, The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services, The United States of America as Represented by the Department of Veterans AffairsInventors: Susan K. Keay, Zoltan Szekely, Maria Michejda
-
Patent number: 8926987Abstract: This invention provides improved replication-competent adenoviral vectors. The improved vectors have both a hybrid regulatory unit that provides for high level transgene expression. The vectors can be use, e.g., for therapeutic or prophylactic purposes.Type: GrantFiled: November 17, 2005Date of Patent: January 6, 2015Assignees: The Government of The United States of America as represented by the Secretary of the Department of Health and Human Services, Istituto Superiore di SanitaInventors: Bo Peng, Rebecca Voltan, Barbara Ensoli, Marjorie Robert-Guroff
-
Patent number: 8427160Abstract: A method of performing high throughput magnetic sensing of one or more samples. The method comprises selecting a first sample having a first bulk magnetic susceptibility, selecting an assay plate having a second bulk magnetic susceptibility matched to the first bulk magnetic susceptibility, the assay plate including multiple wells, introducing the first sample into a plurality of the wells, and performing magnetic sensing on the plurality of wells containing the first sample. Assay plates, caps, kits, and other devices and methods relating to high throughput magnetic sensing are also disclosed.Type: GrantFiled: October 12, 2006Date of Patent: April 23, 2013Assignee: The Government of the United States of America, as represented by the Secretary, Department of Health and Human ServicesInventor: Kenneth W. Fishbein
-
Patent number: 8288359Abstract: The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating inflammatory arthropathies by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.Type: GrantFiled: April 25, 2011Date of Patent: October 16, 2012Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Dennis Klinman, Rainald Zeuner, Daniela Verthelyi, Ihsan Gursel, Mayda Gursel
-
Patent number: 8242778Abstract: An electron paramagnetic resonance imaging system that includes means for continuously irradiating a sample with RF irradiation; means for imposing on the sample a sinusoidally varying magnetic field along with rotating gradients for spatial encoding; means for directly detecting signal data from the sample, without using field modulation, while irradiating the sample with RF radiation continuously, the means for directly detecting having means for sweeping the sinusoidally varying magnetic field; and means for transmitting, receiving and processing the signal data, using means including a digital signal processor.Type: GrantFiled: June 4, 2010Date of Patent: August 14, 2012Assignee: The Government of the United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: Sankaran Subramanian, Nallathamby Devasahayam, Janusz Koscielniak, James B. Mitchell, Murali K. Cherukuri
-
Patent number: 8043623Abstract: Immunogenic T-cell receptor gamma Alternate Reading Frame Protein (TARP) polypeptides are disclosed herein. These immunogenic TARP polypeptides include nine consecutive amino acids of the amino acid sequence set forth as SEQ ID NO: 9 and do not comprise amino acids 1-26 or amino acids 38-58 of SEQ ID NO: 1. Several specific, non-limiting examples of these polypeptides are set forth as SEQ ID NOs: 3-7. Nucleic acids encoding these polypeptides, and host cells transfected with these nucleic acids, are also disclosed. Methods of using these polypeptides, and polynucleotides encoding these polypeptides, for the treatment of breast and prostate cancer are also disclosed.Type: GrantFiled: April 27, 2009Date of Patent: October 25, 2011Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Jay A. Berzofsky, SangKon Oh, Ira Pastan